<DOC>
	<DOCNO>NCT02174731</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy roxadustat compare epoetin alfa treatment anemia chronic kidney disease patient dialysis .</brief_summary>
	<brief_title>Safety Efficacy Study Roxadustat Treat Anemia Patients With Chronic Kidney Disease , Dialysis</brief_title>
	<detailed_description>This Phase 3 , multicenter , randomize , open-label , active-controlled study evaluate safety efficacy roxadustat compare epoetin alfa treatment anemia dialysis patient . Patients hemodialysis ( HD ) peritoneal dialysis ( PD ) treat erythropoietin analogue indication treatment erythropoietin analogue evaluate eligibility randomize 1:1 ratio treatment roxadustat ( discontinuation prior erythropoietin analogue therapy ) active-control group treat epoetin alfa .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Inclusion criterion : Receiving initiate hemodialysis peritoneal dialysis treatment native kidney endstage renal disease least 30 day prior visit 1 . Two central laboratory hemoglobin value screen period , obtain least 7 day apart , must &lt; 12 g/dL patient currently treat erythropoietin analogue &lt; 10 g/dL patient currently treat erythropoietin analogue . Patients consider currently treat receive either Mircera® least 8 week erythropoietin analogue least 4 week prior visit 1 . Ferritin ≥100 ng/mL randomization . Transferrin saturation ( TSAT ) ≥20 % randomization . Serum folate level ≥ low limit normal ( LLN ) randomization . Serum vitamin B12 level ≥LLN randomization . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤3x upper limit normal ( ULN ) , total bilirubin ≤1.5 x ULN randomization . Body weight 45 160 kg . Exclusion criterion : New York Heart Association Class III IV congestive heart failure enrollment Myocardial infarction , acute coronary syndrome , stroke , seizure thrombotic event ( e.g. , deep vein thrombosis pulmonary embolism ) within 12 week prior randomization . History chronic liver disease ( e.g. , chronic infectious hepatitis , chronic autoimmune liver disease , cirrhosis fibrosis liver ) . Known hereditary hematologic disease thalassemia , sickle cell anemia , history pure red cell aplasia know cause anemia chronic kidney disease ( CKD ) . Known untreated retinal vein occlusion know untreated proliferative diabetic retinopathy ( risk retinal vein thrombosis ) . Diagnosis suspicion ( e.g . complex kidney cyst Bosniak Category II F , III IV ) renal cell carcinoma renal ultrasound ( imaging procedure e.g . computerize tomography ( CT ) scan magnetic resonance imaging ( MRI ) ) conduct screen within 12 week prior randomization . Uncontrolled hypertension time randomization , ( define systolic BP ≥180 mmHg diastolic BP ≥100 mmHg repeat measurement postdialysis hemodialysis patient time peritoneal dialysis patient ) , contraindication epoetin alfa treatment ( e.g. , pure red cell aplasia , hypersensitivity know inability tolerate epoetin alfa ) . History prostate cancer , breast cancer malignancy , except follow : cancer determine cured remission ≥5 year , curatively resect basal cell squamous cell skin cancer , cervical cancer situ resect colonic polyp . Positive following : human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) antihepatitis C virus antibody . Chronic inflammatory disease rheumatoid arthritis , systemic lupus erythematosus ( SLE ) , ankylose spondylitis , psoriatic arthritis inflammatory bowel disease determine principal cause anemia . Known hemosiderosis , hemochromatosis hypercoagulable condition . Any prior organ transplant exception renal transplant subsequently remove ( `` explanted '' ) schedule organ transplantation date . Any red blood cell ( RBC ) transfusion screen period . Any current condition lead active significant blood loss . Any prior treatment roxadustat hypoxiainducible factor prolyl hydroxylase inhibitor ( HIFPHI ) . History alcohol drug abuse within 2 year prior randomization Females childbearing potential , unless use contraception detail protocol sexual abstinence . Pregnant breastfeeding female . Known allergy investigational product ingredient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Renal ,</keyword>
	<keyword>CKD ,</keyword>
	<keyword>Epoetin alfa ,</keyword>
	<keyword>Roxadustat ,</keyword>
	<keyword>dialysis ,</keyword>
	<keyword>anemia</keyword>
</DOC>